Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 89

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 4I
Chunk 89
---
 by medical institutions from wholesalers.
​
C.   Organizational Structure
Genmab A/S holds investments either directly or indirectly in the following significant subsidiaries: Genmab B.V. (Utrecht, the Netherlands), Genmab Holding B.V. (Utrecht, the Netherlands), and Genmab US, Inc. (New Jersey, USA). These subsidiaries perform certain research and development, selling, general and administrative, and management activities on behalf of Genmab A/S.
​
​

75

D.   Property And Equipment
​
The following table specifies our material leased facilities and their related activities:
​

         ​             ​                             ​                              ​             ​             ​           ​        
-------------------------------------------------------------------------------------------------------------------------------------
Location               ​   Use of facility                                          ​   Area (in square feet)   ​   Lease expiry date
Valby, Denmark         ​   Corporate headquarters                                   ​                 174,829   ​   February, 2038   
Ballerup, Denmark      ​   Office and laboratory space                              ​                  45,622   ​   June, 2031       
Utrecht, Netherlands   ​   Office, laboratory, and pre-clinical development space   ​                  90,061   ​   May, 2032        
Zeist, Netherlands     ​   Office, laboratory, and pre-clinical development space   ​                  41,437   ​   December, 2025   
Utrecht, Netherlands   ​   Office, laboratory, and pre-clinical development space   ​                  59,352   ​   June, 2032       
Utrecht, Netherlands   ​   Office, laboratory, and pre-clinical development space   ​                  61,795   ​   April, 2032      
Plainsboro, NJ, USA    ​   Office and laboratory space                              ​                 135,136   ​   August, 2031     
Plainsboro, NJ, USA    ​   Office and laboratory space                              ​                 135,476   ​   July, 2036       
Tokyo, Japan           ​   Office space                                             ​                  28,744   ​   June, 2029       
​
We believe that our existing facilities are adequate to meet our current needs and that suitable additional or alternative facilities will be available in the future on commercially reasonable terms to meet our future needs.
​
See Note 3.2 “Property and Equipment” in our Audited Financial Statements for additional details regarding our property and equipment, and other capital